DBV Technologies (DBVT) risk factors

75 risks, 6 new, 6 dropped, 14 reworded since the prior year. DBV prepares for U.S. commercialization of the Viaskin Peanut patch following positive Phase 3 VITESSE results in children aged 4 to 7. Stallergenes Greer intends to discontinue Palforzia commercialization in July 2026. The company relies heavily on Sanofi and FAREVA for manufacturing.

75 risks. DBV Technologies is a clinical-stage biopharmaceutical company focused on its Viaskin technology platform, particularly Viaskin Peanut and Viaskin Milk. The company faces a severe risk of running out of cash, having incurred substantial net losses and an accumulated deficit of $286.4 million. Regulatory hurdles, reliance on third-party manufacturers, and clinical trial safety protocols such as oral food challenges dominate the risk profile.